By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORTBusiness UpdateUpdate on Phase 3 Clinical Trial of M-001BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTPositive Interim Results for CERC-301 in nOHOn April 15, 2019, Cerecor, Inc. (NASDAQ:CERC) announced positive interim results for the Phase 1 study of CERC-301 in Parkinson’s Disease (PD) patients suffering from neurogenic orthostatic hypotension (nOH). The Phase 1 trial is a...
By David Bautz, PhDNASDAQ:DFFNREAD THE FULL DFFN RESEARCH REPORTBusiness UpdateData from First Eight Patients in Phase 3 GBM Trial in mid-2019Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) is currently conducting the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma...
By Brian Marckx, CFANASDAQ:NAOVREAD THE FULL NAOV RESEARCH REPORTFiscal 2018 Results / Business UpdateNanoVibronix (NASDAQ:NAOV) filed their 10-K for the fiscal year ending December 31, 2018. Relative to the financials, revenue was $55k and $318k in Q4 and the full-year 2018, respectively, compared to $70k and $239k in...
By Lisa ThompsonNASDAQ:PIXYREAD THE FULL PIXY RESEARCH REPORT ShiftPixy (NASDAQ:PIXY), again, missed our gross billings and revenue numbers for the quarter and more than compensated with its gross margin performance. We had expected the company to generate $2.5 million in gross margin, but it managed to achieve $3.2 million versus...
By Steven Ralston, CFAOTC:MEECREAD THE FULL MEEC RESEARCH REPORT Over the last six months, the news flow from Midwest Energy Emissions (OTC:MEEC) has been significant and positive in regard to North American contracts and corporate initiatives. In terms of contracts, at least five additional EGUs are under supply contracts, one...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateAdditional P2 Data for VK2809 Presented at EASLOn April 11, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the presentation of new data from the Phase 2 clinical trial of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and hypercholesterolemia. Included...
TSX:NUAG.VOTC:NUPMF Vancouver, British Columbia-based New Pacific Metals Corp. (TSX:NUAG.V) (OTC:NUPMF) is a Canadian company engaged in exploration and development, with properties in Bolivia, Canada and China. The company is optimistic about its primary asset, the Silver Sand project in Bolivia, which it...
By Steven Ralston, CFATSX:WML.V | OTC:WMLLFREAD THE FULL WML.V RESEARCH REPORT Wealth Minerals (TSX:WML.V) (OTC:WMLLF) is a junior mineral exploration company that is well-positioned to benefit from its portfolio of prospective lithium projects in the Lithium Triangle. The company holds control over portions of several lithium salar projects in northern...
By John Vandermosten, CFANASDAQ:TENXREAD THE LATEST TENX RESEARCH REPORT2018 Financial and Operational ReviewDuring 2018 Tenax Therapeutics, Inc. (NASDAQ:TENX) re-aligned the company towards the development of levosimendan for Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Efforts included a successful pre-IND meeting with the FDA in...